NEW DelHI, Phuptjane 22 (Xinhua) - Moetsi oa ente ea India Bharat Biotech's Covaxin o bontšitse katleho ea 77.8 lekholong litekong tsa mohato oa III, mecha ea litaba ea lehae e tlalehiloe ka Labobeli.
"Bharat Biotech's Covaxin e sebetsa ka liperesente tse 77.8 ho sireletsa khahlanong le COVID-19, ho latela lintlha tse tsoang litekong tsa mohato oa III tse entsoeng ho barupeluoa ba 25,800 ho pholletsa le India," ho boletse tlaleho.
Sekhahla sa ts'ebetso se hlahile ka Labobeli kamora hore komiti ea litsebi tsa litaba tsa DCGI (SEC) e kopane le ho buisana ka liphetho.
Feme ea meriana e ne e rometse lintlha tsa teko ea mohato oa III bakeng sa ente ho DCGI mafelong a beke.
Litlaleho li boletse hore k'hamphani e lebelletsoe ho tšoara kopano ea "pele-pele" le balaoli ba Mokhatlo oa Lefatše oa Bophelo ka Laboraro, ho buisana ka litataiso bakeng sa tlhahiso ea ho qetela ea lintlha le litokomane tse hlokahalang.
India e qalile ente e ngata khahlanong le COVID-19 ka la 16 Pherekhong ka ho fana ka liente tse peli tse entsoeng India, e leng Covishield le Covaxin.
Setsi sa Serum sa India (SII) se etsa Covishield ea Univesithi ea AstraZeneca-Oxford, ha Bharat Biotech e sebelisana 'moho le Lekhotla la India la Patlisiso ea Bongaka (ICMR) ho etsa Covaxin.
Ente e entsoeng Russia ea Sputnik V le eona e ile ea phatlalatsoa ka har'a naha.Enditem
Nako ea poso: Jun-25-2021